New Drug Development for Known and Emerging Viruses

· · ·
· 销售商:John Wiley & Sons
电子书
528

关于此电子书

Discusses how to fight Ebola, SARS Corona, and other known or emerging human viruses by building on the successes in antiviral therapy of the past decades

Written by leading medicinal chemists from academia and industry, this book discusses the entire field of antiviral drug discovery and development from a medicinal chemistry perspective, focusing on antiviral drugs, targets, and viral disease mechanisms. It provides an outlook on emerging pathogens such as Ebola, Zika, West Nile, Lassa, and includes a chapter on SARS Coronoavirus-2 causing the present pandemic.

New Drug Development for Known and Emerging Viruses describes the discovery and development process for antiviral agents for different classes of viruses and targets based on the experiences from the nine human viruses for which approved drugs are on the market (HIV, HCV, Influenza, RSV, HBV, HPV, HCMV, HSV, and VZV). It covers the properties and potential of 20 classes of currently approved antivirals, including combination drugs, and looks at novel antiviral strategies against emerging viruses.

  • Covers the entire field of antiviral drug discovery and development
  • Addresses the need for antiviral drugs to combat major health threats such as Ebola, Zika, West Nile, and SARS Coronavirus-2
  • Summarizes the successes of the past 15 years in developing ground-breaking medicines against 9 major human viruses, both from the medicinal chemistry and the pharmacological angle
  • Discusses practical and strategic challenges in the drug discovery and development process, including screening technologies, latency, and toxicity issues

New Developments in Antiviral Drugs is an important book for medicinal chemists, pharmaceutical chemists, virologists, and epidemiologists, and will be of great interest to those in the ;pharmaceutical industry and public health agencies.

作者简介

Helga Rubsamen-Schaeff , PhD, is founding CEO of AiCuris and the chair of AiCuris' Scientific Advisory Board. Before founding AiCuris she served at Bayer as SVP and Head of Infectious Disease Research. Before that time, she was Scientific and Managing Director of the Georg-Speyer-Haus in Frankfurt. A chemist by training, Professor Rubsamen-Schaeff has been professor of biochemistry at the University of Frankfurt since 1988. Her research interests focus on research and development of antiviral drugs, novel resistance-breaking antibiotics, emerging infectious diseases and oncology. Prevymis, a drug against HCMV discovered under her direction has reached the market. Helmut Buschmann, PhD, has over 25 years of international experience in drug discovery research and drug development in the pharmaceutical/biotechnology sectors in different therapeutic areas, from pain research to anti-infectives. Currently, he is Head of Chemistry, Pharmaceutical Development and Patent Affairs at AiCuris and cofounder and co-owner of RD&C Research, Development & Consulting in Vienna.

为此电子书评分

欢迎向我们提供反馈意见。

如何阅读

智能手机和平板电脑
只要安装 AndroidiPad/iPhone 版的 Google Play 图书应用,不仅应用内容会自动与您的账号同步,还能让您随时随地在线或离线阅览图书。
笔记本电脑和台式机
您可以使用计算机的网络浏览器聆听您在 Google Play 购买的有声读物。
电子阅读器和其他设备
如果要在 Kobo 电子阅读器等电子墨水屏设备上阅读,您需要下载一个文件,并将其传输到相应设备上。若要将文件传输到受支持的电子阅读器上,请按帮助中心内的详细说明操作。